Reata Announces First Patient Enrolled in Phase 3 CARDINAL Trial of Bardoxolone Methyl in the Treatment of Chronic Kidney Dis...
August 07 2017 - 5:15PM
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) (“Reata” or the
“Company”) today announced the enrollment of the first patient in
the Phase 3 portion of the CARDINAL trial of bardoxolone methyl
(“bardoxolone”) in patients with chronic kidney disease (“CKD”)
caused by Alport syndrome. The purpose of this study is to
determine the safety and efficacy of bardoxolone in Alport syndrome
patients and to determine if Alport syndrome patients experience
improvements in kidney function compared to placebo.
"We are very pleased to begin enrollment of the
Phase 3 portion of the CARDINAL study, and we are encouraged by the
enthusiasm for bardoxolone that we have experienced within the
renal community. We hope to demonstrate that bardoxolone can
serve as a meaningful new treatment option for patients with Alport
syndrome," said Warren Huff, Reata’s Chief Executive Officer and
President.
About Reata Pharmaceuticals,
Inc.
Reata is a clinical-stage biopharmaceutical company
that develops novel therapeutics for patients with serious or
life-threatening diseases by targeting molecular pathways involved
in the regulation of cellular metabolism and inflammation.
Reata’s two most advanced clinical candidates, bardoxolone
methyl and omaveloxolone, target the important transcription factor
Nrf2 that promotes the resolution of inflammation by restoring
mitochondrial function, reducing oxidative stress, and inhibiting
pro-inflammatory signaling.
Forward-Looking Statements
This press release includes certain disclosures
which contain “forward-looking statements,” including, without
limitation, statements regarding the success, cost and timing of
our product development activities and clinical trials, our plans
to research, develop and commercialize our product candidates, and
our ability to obtain and retain regulatory approval of our product
candidates. You can identify forward-looking statements
because they contain words such as “believes,” “will,” “may,”
“aims,” “plans” and “expects.” Forward-looking statements are
based on Reata’s current expectations and assumptions.
Because forward-looking statements relate to the future, they are
subject to inherent uncertainties, risks, and changes in
circumstances that may differ materially from those contemplated by
the forward-looking statements, which are neither statements of
historical fact nor guarantees or assurances of future
performance. Important factors that could cause actual
results to differ materially from those in the forward-looking
statements include, but are not limited to (i) the timing, costs,
conduct, and outcome of our clinical trials and future preclinical
studies and clinical trials, including the timing of the initiation
and availability of data from such trials; (ii) the timing and
likelihood of regulatory filings and approvals for our product
candidates; (iii) the potential market size and the size of the
patient populations for our product candidates, if approved for
commercial use, and the market opportunities for our product
candidates; and (iv) other factors set forth in Reata’s filings
with the U.S. Securities and Exchange Commission, including its
Annual Report on Form 10-K, under the caption “Risk Factors.”
The forward-looking statements speak only as of the date made and,
other than as required by law, we undertake no obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events, or otherwise.
Contacts
Corporate:
Reata Pharmaceuticals, Inc.
(972) 865-2219
info@reatapharma.com
http://news.reatapharma.com
Investor:
Vinny Jindal
Vice President, Strategy
(855) 55-REATA
ir@reatapharma.com
Media:
Matt Middleman, M.D.
LifeSci Public Relations
(646) 627-8384
matt.middleman@lifescipublicrelations.com
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Reata Pharmaceuticals (NASDAQ:RETA)
Historical Stock Chart
From Apr 2023 to Apr 2024